142 related articles for article (PubMed ID: 32532756)
1. A Patient-Level Model to Estimate Lifetime Health Outcomes of Patients With Type 1 Diabetes.
Tran-Duy A; Knight J; Palmer AJ; Petrie D; Lung TWC; Herman WH; Eliasson B; Svensson AM; Clarke PM
Diabetes Care; 2020 Aug; 43(8):1741-1749. PubMed ID: 32532756
[TBL] [Abstract][Full Text] [Related]
2. Simulating lifetime outcomes associated with complications for people with type 1 diabetes.
Lung TW; Clarke PM; Hayes AJ; Stevens RJ; Farmer A
Pharmacoeconomics; 2013 Jun; 31(6):509-18. PubMed ID: 23585309
[TBL] [Abstract][Full Text] [Related]
3. Assessing the cost-effectiveness of type 1 diabetes interventions: the Sheffield type 1 diabetes policy model.
Thokala P; Kruger J; Brennan A; Basarir H; Duenas A; Pandor A; Gillett M; Elliott J; Heller S
Diabet Med; 2014 Apr; 31(4):477-86. PubMed ID: 24299192
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness of insulin detemir compared to NPH insulin for type 1 and type 2 diabetes mellitus in the Canadian payer setting: modeling analysis.
Tunis SL; Minshall ME; Conner C; McCormick JI; Kapor J; Yale JF; Groleau D
Curr Med Res Opin; 2009 May; 25(5):1273-84. PubMed ID: 19366302
[TBL] [Abstract][Full Text] [Related]
5. Continuous subcutaneous insulin infusion versus multiple daily injections of insulin: economic comparison in adult and adolescent type 1 diabetes mellitus in Australia.
Cohen N; Minshall ME; Sharon-Nash L; Zakrzewska K; Valentine WJ; Palmer AJ
Pharmacoeconomics; 2007; 25(10):881-97. PubMed ID: 17887808
[TBL] [Abstract][Full Text] [Related]
6. Life Expectancy and Lifetime Health Care Expenditures for Type 1 Diabetes: A Nationwide Longitudinal Cohort of Incident Cases Followed for 14 Years.
Ou HT; Yang CY; Wang JD; Hwang JS; Wu JS
Value Health; 2016 Dec; 19(8):976-984. PubMed ID: 27987648
[TBL] [Abstract][Full Text] [Related]
7. The CORE Diabetes Model: Projecting long-term clinical outcomes, costs and cost-effectiveness of interventions in diabetes mellitus (types 1 and 2) to support clinical and reimbursement decision-making.
Palmer AJ; Roze S; Valentine WJ; Minshall ME; Foos V; Lurati FM; Lammert M; Spinas GA
Curr Med Res Opin; 2004 Aug; 20 Suppl 1():S5-26. PubMed ID: 15324513
[TBL] [Abstract][Full Text] [Related]
8. A model to estimate the lifetime health outcomes of patients with type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS) Outcomes Model (UKPDS no. 68).
Clarke PM; Gray AM; Briggs A; Farmer AJ; Fenn P; Stevens RJ; Matthews DR; Stratton IM; Holman RR;
Diabetologia; 2004 Oct; 47(10):1747-59. PubMed ID: 15517152
[TBL] [Abstract][Full Text] [Related]
9. Development and validation of a cost-utility model for Type 1 diabetes mellitus.
Wolowacz S; Pearson I; Shannon P; Chubb B; Gundgaard J; Davies M; Briggs A
Diabet Med; 2015 Aug; 32(8):1023-35. PubMed ID: 25484028
[TBL] [Abstract][Full Text] [Related]
10. Health-economic comparison of continuous subcutaneous insulin infusion with multiple daily injection for the treatment of Type 1 diabetes in the UK.
Roze S; Valentine WJ; Zakrzewska KE; Palmer AJ
Diabet Med; 2005 Sep; 22(9):1239-45. PubMed ID: 16108855
[TBL] [Abstract][Full Text] [Related]
11. Association of diabetes type and chronic diabetes complications with early exit from the labour force: register-based study of people with diabetes in Finland.
Kurkela O; Forma L; Ilanne-Parikka P; Nevalainen J; Rissanen P
Diabetologia; 2021 Apr; 64(4):795-804. PubMed ID: 33475814
[TBL] [Abstract][Full Text] [Related]
12. Large impact of antidiabetic drug treatment and hospitalizations on economic burden of diabetes mellitus in The Netherlands during 2000 to 2004.
van der Linden MW; Plat AW; Erkens JA; Emneus M; Herings RM
Value Health; 2009 Sep; 12(6):909-14. PubMed ID: 19508664
[TBL] [Abstract][Full Text] [Related]
13. Development of a life expectancy table for individuals with type 1 diabetes.
Tran-Duy A; Knight J; Clarke PM; Svensson AM; Eliasson B; Palmer AJ
Diabetologia; 2021 Oct; 64(10):2228-2236. PubMed ID: 34309688
[TBL] [Abstract][Full Text] [Related]
14. Long-term Cost-Effectiveness of Dexcom G6 Real-time Continuous Glucose Monitoring Versus Self-Monitoring of Blood Glucose in Patients With Type 1 Diabetes in the U.K.
Roze S; Isitt J; Smith-Palmer J; Javanbakht M; Lynch P
Diabetes Care; 2020 Oct; 43(10):2411-2417. PubMed ID: 32647050
[TBL] [Abstract][Full Text] [Related]
15. Diabetes, healthcare cost and loss of productivity in Sweden 1987 and 2005--a register-based approach.
Bolin K; Gip C; Mörk AC; Lindgren B
Diabet Med; 2009 Sep; 26(9):928-34. PubMed ID: 19719715
[TBL] [Abstract][Full Text] [Related]
16. Clinical Outcome and Cost-Effectiveness Analysis of CSII Versus MDI in Children and Adolescent With Type 1 Diabetes Mellitus in a Public Health Care System of China.
Hu S; Yang H; Chen Z; Leng X; Li C; Qiao L; Lv W; Li T
Front Endocrinol (Lausanne); 2021; 12():604028. PubMed ID: 33859614
[TBL] [Abstract][Full Text] [Related]
17. Development and validation of risk assessment models for diabetes-related complications based on the DCCT/EDIC data.
Lagani V; Chiarugi F; Thomson S; Fursse J; Lakasing E; Jones RW; Tsamardinos I
J Diabetes Complications; 2015; 29(4):479-87. PubMed ID: 25772254
[TBL] [Abstract][Full Text] [Related]
18. Costs and outcomes of "intermediate" vs "minimal" care for youth-onset type 1 diabetes in six countries.
Gregory GA; Guo J; Klatman EL; Ahmadov GA; Besançon S; Gomez ED; Fawwad A; Ramaiya K; Wijesuriya MA; Orchard TJ; Ogle GD
Pediatr Diabetes; 2020 Jun; 21(4):628-636. PubMed ID: 31970828
[TBL] [Abstract][Full Text] [Related]
19. Development and validation of the Economic Assessment of Glycemic Control and Long-Term Effects of diabetes (EAGLE) model.
Mueller E; Maxion-Bergemann S; Gultyaev D; Walzer S; Freemantle N; Mathieu C; Bolinder B; Gerber R; Kvasz M; Bergemann R
Diabetes Technol Ther; 2006 Apr; 8(2):219-36. PubMed ID: 16734551
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
